The global osteoporosis drugs market size is anticipated to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing cases of osteoporosis disease and rising demand for drugs for the treatment of the disease.
Osteoporosis is a type of disorder that causes a high chance of bones fracture in post menopause women, geriatric population, and others. In this condition, patients normally tend to break their bones, forearms, wrist, and spine of the body. It is a metabolic disease that causes a decrease in bone mineral density leading to fracture.
As per the report published by International Osteoporosis Foundation, in 2020, there are 25% of women and 5% of men aged above 65 years are suffering from osteoporosis disorders. Furthermore, in October 2020, the Italian pharmaceutical regulatory body has granted permission for the raoxifene clinical trials on humans. Introduction of a generic osteoporosis medicine is expected to be helpful in COVID-19 treatment and make patients less contagious.
However, multiple therapy procedures are being tested all around the world in order to find a reliable COVID-19 treatment. Several studies have suggested that, in addition to antiviral therapies, other medications such as osteoporosis drugs is expected to be useful in the treatment of COVID-19.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing clinical trials and development of improved diagnostic facilities provided by private & public medical institutions are propelling the market growth.
- Ongoing awareness campaigns related to the treatment of osteoporosis disorder is one of the factors fueling the growth of the market.
- Rising technological advancement and introduction of new drugs by pharmaceutical industry with better efficacy to treat osteoporosis is another major factor triggering the market growth.
- Expiring patents of robust drugs is expected to hamper the market growth in the coming years.
- Adverse side effects of medications and stringent government regulations along with delaying in drug approvals are some of the key challenges that can hinder the market expansion.
- Increasing incidences of osteoporosis condition triggers the manufactures across world to focus more on research & development programs for drugs treatment. Thus, it presents tremendous opportunity for the market growth in the near future.
Scope of Osteoporosis Drugs Market Report
The report on the global osteoporosis drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Osteoporosis Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Products (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Inhibitors Modulator, Generics, Branded, Calcitonin, and Rank Ligand Inhibitors)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Actavis PLC.; Pfizer Inc.; Amgen Inc.; Eli Lily and Co.; Radius Health Inc.; F. Hoffmann La Roche; Merck & Co.; Teva Pharmaceutical Industries Ltd.; Novartis International AG; and GlaxoSmithKline PLC.
Osteoporosis Drugs Market Segment Insights
Rank ligand inhibitors segment is projected to expand at a considerable CAGR
On the basis of products, the global osteoporosis drugs market is segmented into bisphosphonates, parathyroid hormone therapy, selective estrogen inhibitors modulator, generics, branded, calcitonin, rank ligand inhibitors (RANKL). The RANKL segment is projected to expand at a considerable CAGR during the forecast period due to the high successful rate associated with this drug treatment.
It is used for the treatment of osteoporosis patients with high risk of bone fracture. Other factors such as increasing bone mineral density, reducing cell bone turnover, and compatibility with other drugs to get a synergistic effect on the overall treatment are expected to propel the growth of the segment.
According to a study conducted by the Hospital Del Mar, a general hospital in Spain in 2020, Denosumab targets the RANKL system, which is very important to maintain balance in the skeletal system. Furthermore, it impacts the immune system and is involved in lymph node formation and T-cell activation.
The inhibition of this system lowers pro-inflammatory cytokines in the body and aids in inflammation control, which is one of the main causes of COVID-19. Thus, it is anticipated to increase the usage of this drug and up surge the segment growth during the forecast period.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the factors such as increasing cases of osteoporosis patients, well- established healthcare facilities, presence of key players, and availability of branded drugs in the region.
For example, according to the report published by the National Osteoporosis Foundation (NOF) in 2020, there were more than 10 million people suffering from osteoporosis in the US. Thus, it is expected to fuel the market growth in the region.
However, the market of Asia Pacific is estimated to expand at a considerable CAGR in coming years. This growth of the region is attributed to the geographical expansion of market leaders, growing investment in R&D and efforts to sell branded drugs & generic treatments at an affordable cost in the region.
The global osteoporosis drugs market has been segmented on the basis of
- Parathyroid Hormone Therapy
- Selective Estrogen Inhibitors Modulator
- Rank Ligand Inhibitors
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Actavis PLC.
- Pfizer Inc.
- Amgen Inc.
- Eli Lily and Co.
- Radius Health Inc.
- F. Hoffmann La Roche
- Merck & Co.
- Teva Pharmaceutical Industries Ltd.
- Novartis International AG
- GlaxoSmithKline PLC.
Some of the key players dominating the osteoporosis drugs market are Actavis PLC.; Pfizer Inc.; Amgen Inc.; Eli Lily and Co.; Radius Health Inc.; F. Hoffmann La Roche; Merck & Co.; Teva Pharmaceutical Industries Ltd.; Novartis International AG; and GlaxoSmithKline PLC. Some of these main players have adopted several business strategies including partnerships, products launching, mergers, and capacity expansion to expand their market coverage globally.
For instance, Cadila Pharmaceuticals Ltd., an Ahmedabad-based company, launched an osteoporosis biosimilar of Forteo in August 2020, with an aim to treat patients with high risk of fracture and osteoporosis. Teriparatide Injection, also known as PF708 and bonsity, was launched by Alvogen in the United States in June 2020. It was a prescription drug licensed for a variety of applications such as prevention of bone fractures in postmenopausal women with the disease.